Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 5/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 9/20 | 0.42 |
| ▸ | MMP3 | P08254 | 4/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23008343 | 0.90 | CASP3 (0.46) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL22753477 | 0.87 | CASP3 (0.44) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL23381000 | 0.85 | CASP3 (0.42) | CASP3CASP1CASP9MMP1MMP8 | |
| SCHEMBL20756587 | 0.85 | CASP3 (0.46) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL20614509 | 0.82 | MMP1 (0.49) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL20614625 | 0.82 | MMP1 (0.49) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL22753470 | 0.81 | CASP3 (0.49) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL22753468 | 0.80 | CASP3 (0.49) | NAALAD2CASP3CASP1CASP9MMP1 | |
| SCHEMBL29311897 | 0.79 | MMP2 (0.48) | NAALAD2MMP1MMP8ACEMMP2 | |
| SCHEMBL20614626 | 0.75 | OPRD1 (0.48) | CASP3MMP1MMP8CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | NAALAD2 411/4885CASP3 623/4885CASP1 1529/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | NAALAD2 411/4885CASP3 623/4885CASP1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.